Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study.
Saved in:
| Title: | Cabozantinib Plus Atezolizumab or Cabozantinib Alone in Patients With Advanced NSCLC Previously Treated With an Immune Checkpoint Inhibitor: Results From the Phase 1b COSMIC-021 Study. |
|---|---|
| Authors: | Neal JW; Division of Oncology, Stanford Cancer Institute, Palo Alto, California., Santoro A; Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Milan, Italy.; IRCCS Humanitas Research Hospital- Humanitas Cancer Center, Rozzano, Milan, Italy., Gonzalez-Cao M; Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain., Lim FL; Barts Health NHS Trust, St Bartholomew's Hospital, London, United Kingdom., Fang B; Astera Cancer Care, East Brunswick, New Jersey., Gentzler RD; Division of Hematology Oncology, University of Virginia Cancer Center, Charlottesville, Virginia., Goldschmidt J; Department of Medical Oncology, Blue Ridge Cancer Care, Blacksburg, Virginia., Khrizman P; MD Anderson Cancer Center at Cooper, Camden, New Jersey., Proto C; Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy., Patel S; Division of Medical Oncology, The Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Puri S; Division of Medical Oncology, The Huntsman Cancer Institute at the University of Utah, Salt Lake City, Utah., Liu SV; Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia., Massarelli E; Department of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, California., Williamson D; Department of Biostatistics, Exelixis Inc, Alameda, California., Schwickart M; Department of Translational Medicine, Exelixis Inc, Alameda, California., Scheffold C; Department of Clinical Development, Exelixis Inc, Alameda, California., Andrianova S; Department of Clinical Development, Exelixis Inc, Alameda, California., Felip E; Medical Oncology Service, Vall d'Hebron Institute of Oncology (VIHO), Vall d'Hebron Barcelona Hospital Campus, Universitat Autonoma de Barcelona, Barcelona, Spain. |
| Source: | JTO clinical and research reports [JTO Clin Res Rep] 2024 Mar 20; Vol. 5 (10), pp. 100666. Date of Electronic Publication: 2024 Mar 20 (Print Publication: 2024). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Inc Country of Publication: United States NLM ID: 101769967 Publication Model: eCollection Cited Medium: Internet ISSN: 2666-3643 (Electronic) Linking ISSN: 26663643 NLM ISO Abbreviation: JTO Clin Res Rep Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
